P632 Etrasimod induction therapy in moderately to severely active Crohn’s disease: results from a phase 2, randomised, double-blind substudyGeert D’Haens, Séverine Vermeire, D Dray et al.|Journal of Crohn s and Colitis|2023Cited by 20
Etrasimod as a treatment for eosinophilic oesophagitis (VOYAGE): a double-blind, placebo-controlled, randomised, phase 2 trialEvan S. Dellon, Ikuo Hirano, Margaret H. Collins et al.|The Lancet. Gastroenterology & hepatology|2025Cited by 15
635 EFFICACY AND SAFETY OF THE SELECTIVE SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATOR, ETRASIMOD, IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS OVER 52 WEEKS IN THE PHASE 2 VOYAGE STUDYEvan S. Dellon, Ikuo Hirano, Margaret H. Collins et al.|Gastroenterology|2024Cited by 3
Etrasimod as a treatment for eosinophilic oesophagitis (VOYAGE): a double-blind, placebo-controlled, randomised, phase 2 trialEvan S Dellon, Ikuo Hirano, Margaret H. Collins et al.|Unknown|2025Cited by 0